Form 4: Amicus Therapeutics CDO Sells Shares for Tax Obligations

Amicus Therapeutics' Chief Development Officer, Jeff Castelli, reported the disposition of 29,007 common shares at $14.27 per share to cover tax liabilities.

Summary

• Jeff Castelli, Chief Development Officer of Amicus Therapeutics, Inc. (FOLD), reported two transactions involving the disposition of common stock.
• On January 2, 2026, 6,905 shares were disposed of at a price of $14.27 per share.
• On January 3, 2026, an additional 23,102 shares were disposed of at the same price of $14.27 per share.
• These transactions, totaling 29,007 shares, were executed under Transaction Code 'F', indicating they were likely for tax withholding purposes related to equity awards.
• Following these transactions, Jeff Castelli beneficially owns 409,311 shares of Amicus Therapeutics common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were disposed of, it was for tax purposes and not a discretionary sale, which is a routine event. The executive still holds a substantial number of shares, indicating continued alignment.

Positives

• The transactions were non-discretionary, executed under Transaction Code 'F', which typically signifies shares withheld for tax obligations related to equity awards, rather than a voluntary sale by the officer.
• The transactions were conducted under a Rule 10b5-1(c) plan, indicating pre-planned sales to avoid accusations of insider trading.
• The Chief Development Officer retains a significant beneficial ownership of 409,311 shares, demonstrating continued alignment with shareholder interests.

Negatives

• The disposition of shares, even for tax purposes, reduces the direct beneficial ownership of a key executive.

Future Outlook

NA

Industry Context

This Form 4 filing reflects routine insider transaction reporting for a biopharmaceutical company, common across the industry when executives receive equity compensation and must cover tax liabilities. It does not indicate any specific industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The reduction in direct beneficial ownership by a key executive is minor and for tax purposes, not indicating a lack of confidence. The executive still holds a significant stake.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a Chief Development Officer to cover tax obligations related to equity compensation, executed under a pre-arranged 10b5-1 plan. It does not signal any change in the company's fundamentals, strategic direction, or the executive's confidence in the company. The executive retains a substantial holding. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Amicus Therapeutics, FOLD, Jeff Castelli, Insider Trading, Form 4, Stock Sale, Officer Transaction, Equity Compensation, Tax Withholding, Rule 10b5-1